# A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease

> **NCT06055985** · PHASE2 · COMPLETED · sponsor: **UCB Biopharma SRL** · enrollment: 207 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **OTHER:** Placebo
- **DRUG:** UCB0022

## Key facts

- **NCT ID:** NCT06055985
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-17
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-04-11
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06055985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06055985, "A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06055985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*